Published in Vaccine Weekly, April 26th, 2006
Eligible Avantogen shareholders will be offered one new share for every four shares they hold, as at April 6, 2006, at an issue price of AUD0.105 cents per share. Shareholders will also receive 1 option for every 2 rights they take up. The option will be listed, have an exercise price of AUD0.25 cents and will expire on December 31, 2007. The rights issue has been fully underwritten by BBY Limited.
Avantogen CEO, Dr. Leonard Firestone, said, "The funds will be used to consummate our recently announced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly